AB Science SA

AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND

02 Sep 2021 11:59:01 By Nasdaq GlobeNewswire

AB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis

25 Aug 2021 12:46:55 By Nasdaq GlobeNewswire

AB Science announces that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in ALS

23 Aug 2021 13:43:09 By Nasdaq GlobeNewswire

AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib

19 Aug 2021 11:51:36 By Nasdaq GlobeNewswire

AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders

06 Aug 2021 13:02:25 By Nasdaq GlobeNewswire

AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC

29 Jul 2021 12:06:56 By Nasdaq GlobeNewswire

AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)

22 Jul 2021 12:10:35 By Nasdaq GlobeNewswire

AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern

20 Jul 2021 12:08:07 By Nasdaq GlobeNewswire

AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo

19 Jul 2021 12:12:44 By Nasdaq GlobeNewswire

AB Science announces the validation of its Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France

12 Jul 2021 02:00:28 By Nasdaq GlobeNewswire

AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib

28 Jun 2021 13:59:14 By Nasdaq GlobeNewswire

AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting

10 Jun 2021 12:54:29 By Nasdaq GlobeNewswire

AB Science is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib

08 Jun 2021 02:30:40 By Nasdaq GlobeNewswire

AB Science will host a live webcast on June 3, 2021 following the voluntary hold in the clinical studies of masitinib

02 Jun 2021 09:32:44 By Nasdaq GlobeNewswire

AB Science announces a voluntary hold in the clinical studies of masitinib worldwide

01 Jun 2021 00:59:55 By Nasdaq GlobeNewswire

AB Science communicates results from Phase 3 study evaluating masitinib in prostate cancer

26 May 2021 13:18:48 By Nasdaq GlobeNewswire

AB Science will host a live webcast on Tuesday May 25, 2021 on masitinib results in Prostate Cancer

21 May 2021 12:01:41 By Nasdaq GlobeNewswire

AB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual Meeting

20 May 2021 12:06:59 By Nasdaq GlobeNewswire

AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities

30 Apr 2021 12:45:24 By Nasdaq GlobeNewswire

AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint

29 Apr 2021 13:05:11 By Nasdaq GlobeNewswire